Questionnaire-based behaviour analysis of Cavalier King Charles spaniels with neuropathic pain due to Chiari-like malformation and syringomyelia

Rutherford, Lynda; Wessmann, Annette; Rusbridge, Clare; McGonnell, Imelda M.; Abeyesinghe, Siobhan; Burn, Charlotte C.; Volk, Holger A.

doi:10.1016/j.tvjl.2012.05.018

Cited by 40 publications

(43 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…10,23-25 The questionnaire used in the present study has been already validated in dogs with heart failure. 10 All studies recommend using the owner-perceived quality of life score for disease management.…”

Section: Discussionmentioning

confidence: 99%

Quality of Life Score as a Predictor of Death in Dogs with Degenerative Mitral Valve Disease

Marcondes-Santos¹,

Takada²,

Fragata³

et al. 2017

Arquivos Brasileiros De Cardiologia

View full text Add to dashboard Cite

BackgroundThe knowledge of the variables predicting mortality is important in clinical practice and for therapeutic monitoring in mitral valve disease.ObjectivesTo determine whether a quality of life score evaluated with the Functional Evaluation of Cardiac Health questionnaire would predict mortality in dogs with degenerative mitral valve disease (DMVD).MethodsThirty-six client-owned dogs with mitral valve disease underwent clinical, laboratory, and echocardiographic evaluations at baseline and were monitored for 6 months. Cardiovascular death was the primary outcome.ResultsThe 36 dogs were classified as survivors or nonsurvivors. Higher values of the following variables were obtained at baseline in the nonsurviving group (12 dogs): amino-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, plasma norepinephrine, heart rate, quality of life score, diastolic left ventricular internal dimension to aortic root ratio, systolic left ventricular internal dimension to aortic root ratio, and left atrium to aortic root ratio. NT-proBNP levels and quality life score were independently associated with death in the multivariable analysis.ConclusionThe quality life score was an independent variable for cardiac death in dogs with DMVD. This result is encouraging, as this score is easy to apply and does not require any technology, only a veterinarian and an observant owner.

show abstract

Section: Discussionmentioning

confidence: 99%

Quality of Life Score as a Predictor of Death in Dogs with Degenerative Mitral Valve Disease

Marcondes-Santos¹,

Takada²,

Fragata³

et al. 2017

Arquivos Brasileiros De Cardiologia

View full text Add to dashboard Cite

show abstract

“…Owners were questioned on their dog’s anxiety-related behaviour before and during imepitoin treatment using five of the eleven C-BARQ behavioural measures: ‘Dog directed fear’, ‘Stranger directed fear’; ‘Non-social fear’; ‘Pain sensitivity’ and ‘Separation related behaviour’. The C-BARQ has previously been used to quantify neurobehavioral changes in dogs with neurological disease, including IE and syringomyelia [11, 28] and to quantify the impact of a ketogenic dietary therapy upon the behaviour of dogs with IE in a placebo-controlled crossover trial [29]. …”

Section: Methodsmentioning

confidence: 99%

Investigating the potential of the anti-epileptic drug imepitoin as a treatment for co-morbid anxiety in dogs with idiopathic epilepsy

2017

Self Cite

View full text Add to dashboard Cite

BackgroundBehavioural changes associated with idiopathic epilepsy (IE) have been identified in dogs, with fear and anxiety-related problems seen in both drug-naïve dogs and dogs treated with anti-epileptic drugs (AEDs). Treating anxiety-related behaviour in dogs with IE may be challenging, as seizures are a contraindication for many conventional anxiolytic drugs. In addition, many dogs with IE are already treated with AEDs to reduce their seizure frequency, which may have negative effects if used in polytherapy. Imepitoin is low-affinity partial agonist at the benzodiazepine (BDZ) site of the GABAA receptor, and has been demonstrated to have both anticonvulsant and anxiolytic effects in laboratory rodents. Imepitoin has been developed for the treatment of IE in dogs, with demonstrated anticonvulsant effects and high tolerability and safety. To date, imepitoin’s potential to reduce anxiety in dogs with IE has not been investigated. An online survey was conducted to investigate the effect of imepitoin on fear and anxiety-related behaviours in dogs with IE. Eighty-five valid responses were received from owners of dogs with IE currently treated with imepitoin. Anxiety-related behaviour was quantified before and during imepitoin treatment using a validated questionnaire tool (C-BARQ).ResultsNo differences were observed in the five fear/anxiety-related measures between the two time periods (before vs. during treatment) for dog directed fear, stranger directed fear, non-social fear, pain sensitivity and separation related behaviour. A median 45% reduction in seizure frequency/month was observed following imepitoin treatment; however, imepitoin did not appear effective in reducing seizure frequency in a minority of cases. Polyphagia was the most common chronic side effect, and more side effects were reported in polytherapy cases.ConclusionsImepitoin does not appear to improve anxiety-related behaviour in dogs with IE treated with this medication for its anti-epileptic effects. Investigating the effects of imepitoin upon the behaviour of dogs with recognised behavioural anxiety-related problems (e.g. specific fears and phobias, separation related behaviours), in both healthy dogs and dogs with epilepsy is required to further explore any potential anxiolytic effects of this medication.

show abstract

“…A major challenge in determining whether treatment options are successful is the difficulty in documenting and quantifying neuropathic pain in these dogs. Questionnaire tools completed by owners have been developed,8, 19, 20, 21 but more objective quantification using QST is lacking. Thermal and mechanical testing has been shown to be reliable and discriminatory in dogs with other pain disorders 22, 23, 24, 25, 26, 27, 28, 29.…”

Section: Introductionmentioning

confidence: 99%

Investigation of sensory thresholds in Cavalier King Charles Spaniels with and without Chiari‐like malformations and syringomyelia

Sparks

Gorney

Williams

et al. 2018

Veterinary Internal Medicne

View full text Add to dashboard Cite

BackgroundCavalier King Charles Spaniels (CKCS) suffer pain associated with Chiari‐like malformation and syringomyelia (CMSM). People suffer from a similar condition and describe numerous sensory abnormalities. Sensory changes have not been quantified in affected CKCS.ObjectivesTo use quantitative sensory testing (QST) to quantify thermal and mechanical thresholds in CKCS and to compare QST in dogs with and without syringomyelia (SM).AnimalsForty‐four CKCS.MethodsProspective study. Dogs underwent neurological examinations and craniocervical magnetic resonance imaging (MRI). Thermal testing was performed over the humerus and thorax (n = 32); mechanical testing was performed on the paw and neck (n = 44). Latencies, thresholds, and response rates were compared with presence and severity of SM on MRI, presence of pain reported by the owner and pain identified on examination.ResultsThirty dogs had SM, 30 were painful on examination, 29 were owner‐reported symptomatic. Thermal and mechanical variables were not significantly different based on presence or severity of SM. Dogs with pain on examination had decreased mechanical thresholds on the paw (0.38 kg, SD = 0.18) and neck (2.05 kg, SD = 0.74) compared to thresholds of dogs without pain on examination on the paw (0.60 kg, SD = 0.30) and neck (2.72 kg, SD = 0.57; P = .021).Conclusions and Clinical ImportanceMechanical and thermal sensitivity does not appear to be related to the presence of SM, but mechanical sensitivity appears to be related to the presence of pain and clinical signs. Mechanical testing may be useful for assessing sensory abnormalities during clinical trials.

show abstract

Questionnaire-based behaviour analysis of Cavalier King Charles spaniels with neuropathic pain due to Chiari-like malformation and syringomyelia

Cited by 40 publications

References 26 publications

Quality of Life Score as a Predictor of Death in Dogs with Degenerative Mitral Valve Disease

Quality of Life Score as a Predictor of Death in Dogs with Degenerative Mitral Valve Disease

Investigating the potential of the anti-epileptic drug imepitoin as a treatment for co-morbid anxiety in dogs with idiopathic epilepsy

Investigation of sensory thresholds in Cavalier King Charles Spaniels with and without Chiari‐like malformations and syringomyelia

Contact Info

Product

Resources

About